-- The NEW Official Alizyme Thread! --

Pin (Post 4719) I drew back from making a prediction for 2004 but as you appear to suggest around 340p I will disclose that I expect 400p to 500p. I am taking into account the following during 2004: expected out-licensing deals for at least three drugs; probable profitability; growing institutional interest; broad, late stage and lowish risk pipeline; new products to be introduced, further reducing risk; strong cash position; and market sentiment. In addition, the lack of any expected trial results until Q1 2005 (PIIa ATL-104) means there is no potential negative news on the horizon imo (albeit I am optimistic about those particular results).

I do not necessarily view 400p to 500p as a year end figure; it could be reached sooner imo. I consider that a takeover bid remains a real possibility and could push the price higher than 500p.